Clinical Trials Browser

Nasopharyngeal Carcinoma

Advanced Refractory Solid Tumors

Colorectal Neoplasms

Advanced or Metastatic Solid Tumors

Advanced Renal Cell Carcinoma (aRCC)

Osteosarcoma

Gastrointestinal Stromal Tumors

Cholangiocarcinoma

Biliary Tract Neoplasms

Biliary Tract Neoplasms

Endometrial Neoplasms

Advanced or Metastatic Solid Tumors

Stomach Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Sarcoma, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Colonic Neoplasms

Colorectal Neoplasms

Gastrointestinal Neoplasms

Pancreatic Neoplasms

Neoplasm Metastasis

Colorectal Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Carcinoma, Ovarian Epithelial

Rectal Neoplasms

Lung Neoplasms

Uterine Cervical Neoplasms

Rectal Neoplasms

Uterine Cervical Neoplasms

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Ovarian Epithelial

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Advanced Pancreatic Cancer

Solid Tumors

Squamous Non-small Cell Lung Cancer

Advanced or Metastatic Solid Tumors

Solid Tumors

Neoplasms, Multiple Primary

HER2-positive Breast Cancer

Clinical Trials

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

CEIL

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

KN035-BTC

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

SPRING

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

ENVASARC

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

TRACE-LE

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

CPOG035-01

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer